# BILIRUBIN - URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE (*UGT1A1*) GENE MUTATIONS AMONG NEWBORN BABIES IN THE MALAY POPULATION IN KELANTAN WITH HYPERBILIRUBINAEMIA

**SURINI YUSOFF** 

**UNIVERSITI SAINS MALAYSIA** 

2006

## BILIRUBIN - URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE (*UGT1A1*) GENE MUTATIONS AMONG NEWBORN BABIES IN THE MALAY POPULATION IN KELANTAN WITH HYPERBILIRUBINAEMIA

by

SURINI YUSOFF

Thesis submitted in fulfillment of the requirements for the degree of Master of Science

September 2005

### Dedication

For my beloved mum and dad (Salehah Mat Hassan and Yusoff Mat Hassan), you are everything in my life. My younger brothers, Zuri, Roslee, Zaidi and Mohd Jailani, I love you all.

Surini 2005

#### ACKNOWLEDGEMENTS

#### In the name of Allah, The Most Gracious, The Most Merciful

A very grateful thanks to my supervisor, Associate Professor Dr Hans Amin Van Rostenberghe, a neonatologist and lecturer at Pediatric Department, Health Campus, Universiti Sains Malaysia and co-supervisor, Dr Narazah Mohamad Yusoff, haematologist and lecturer at Advanced Medical and Dental Institute (Clinical Centre), Penang, for their valuable guidance with constructive criticisms and constant encouragement.

My warmest gratitude to Associate Professor Dr Nik Zainal Abidin Nik Ismail, the previous Head of Pediatric Department. My very special thanks to the entire medical staff at Neonatal Intensive Care Unit (NICU), 1 Timur Belakang (1TB) ward and labor room for their assistance. The fellow staff at Pediatric Research Office, Human Genome Center and Haematology Laboratory needs a special mention for their technical support.

I have no words to express my feelings to my beloved mum and dad, Salehah Mat Hassan and Yusoff Mat Hassan and all my younger brothers for their love, care and support. I take this opportunity to thank all my friends who helped me either directly or indirectly and I wish them good luck in their venture. Really, I enjoyed working with all of them. Last but not least, I thank you for the financial support through the IRPA Grant (No: 304/PPSP/6131289) and the Academic Staff Training Scheme (ASTS) award without which this study would have become impossible.

## TABLE OF CONTENTS

		PAGE
DEDI	CATION	ii
ACK	NOWLEDGEMENTS	iii
TABL	E OF CONTENTS	iv
LIST	OF TABLES	х
LIST	OF FIGURES	xii
LIST	OF PLATES	xv
LIST	OF ABBREVIATIONS	xvi
ABST	RAK	xvii
ABST	RACT	xix
CHAI	PTER I INTRODUCTION	
1.1	Background of the study	1
1.2	Bilirubin metabolism	4
1.3	Clinical aspects of neonatal jaundice	8
	1.3.1 Unconjugated hyperbilirubinaemia	8
	(Indirect hyperbilirubinaemia)	
	1.3.2 Conjugated hyperbilirubinaemia	9
	(Direct hyperbilirubinaemia)	
1.4	Common causes of neonatal jaundice	12
	1.4.1 Physiological jaundice	12
	1.4.2 Pathological causes	13
	1.4.2.1 Haemolytic causes	13

	1.4.2.1(b) Rhesus incompatibility	13
	1.4.2.1(c) Glucose-6-phosphate	13
	dehydrogenase deficiency	
	1.4.2.1(d) Other causes of haemolysis	16
	1.4.2.2 Non-haemolytic causes of neonatal jaundice	17
1.5	Clinical syndromes associated with mutations in the	17
	UGT1A1 gene	
	1.5.1 Crigler-Najjar syndrome	17
	1.5.2 Gilbert syndrome	18
1.6	The UGT1A1 gene	21
	1.6.1 TATA box in the promoter region of UGT1A1 gene	25
	1.6.2 The G71R mutation in exon 1 of UGT1A1 gene	26
	1.6.3 The G493R mutation in exon 5 of UGT1A1 gene	27
	1.6.4 Selection of the three mutations for this study	27
1.7	Aim and objectives	28
	1.7.1 Aim of the research	28
	1.7.2 Specific objectives	28
СНА	PTER II MATERIALS AND METHODS	
2.1 \$	Study Design	30
2.2	Vaterials	31
	2.2.1 Subject selection	31
	2.2.2 Sample size estimation	34
2.3	Methodology	35
	2.3.1 Blood Sampling	35
	2.3.2 Buffy coat preparation	35

2.3.3 DNA extraction	36
2.3.3.1 Reagents for DNA extraction	36
2.3.3.2 Preparation of reagents	36
2.3.3.2 (a) QIAGEN Protease	36
2.3.3.2 (b) Buffer AW1	36
2.3.3.2 (c) Buffer AW2	37
2.3.3.3 DNA extraction protocols	37
2.3.4 Determination of DNA concentration and purity	38
2.3.4.1 Use of spectrophotometer	39
2.3.4.2 Gel electrophoresis for genomic DNA	39
2.3.4.2(i) Reagents for gel electrophoresis	39
2.3.4.2(ii) Preparation of reagents	40
2.3.4.2(ii) a) 10X Tris Borate EDTA	40
(TBE) buffer	
2.3.4.2(ii) b) 1X Tris Borate EDTA	40
(TBE) buffer	
2.3.4.2(ii) c) 1.8% of an agarose gel	40
2.3.4.2(iii) Gel electrophoresis protocols	41
2.3.5 Polymerase Chain Reaction (PCR) Amplification	41
2.3.5(a) Amplification of TATA box promoter region	43
of UGT1A1 gene	
2.3.5(b) Amplification of Exons 1 and 5 of UGT1A1	45
gene	
2.3.5.1 Gel Electrophoresis for PCR product	47
2.3.6 GeneScan analysis for TATA box promoter region of	47

2.3.6.1 Purification	48
2.3.6.1(a) Reagents for PCR purification using	48
a microcentrifuge	
2.3.6.1(b) PCR purification protocol	48
2.3.7 Denaturing high performance liquid chromatography	49
(DHPLC) for exons 1 and 5 of the UGT1A1 gene	
2.3.7.1 Reagents and materials for DHPLC	49
2.3.7.2 DHPLC protocols	50
2.3.7.2(a) Temperature optimization	50
2.3.7.2(b) The running of the sample	54
2.3.7.3 Results analysis	54
2.3.8 Sequencing analysis	55
2.3.8.1 Purification	55
2.3.8.2 Cycle sequencing for Single and	55
Double – Stranded DNA	
2.3.8.3 Ethanol / EDTA Precipitation	56
2.3.8.3(a) Reagents for ethanol / EDTA	56
precipitation	
2.3.8.3(a) i Preparation 70%	56
ethanol	
2.3.8.3(b) Ethanol/EDTA precipitation protocol	56
2.3.9 Statistical analysis	57
2.3.10 Instruments, kits and reagents that have been used in this study	58

## **CHAPTER III RESULTS**

3.1 Isolation and amplification of DNA	60
3.1.1 Quantification of genomic DNA on agarose gel	60
3.2 TATA box promoter region of UGT1A1 gene	62
3.2.1 PCR amplification and visualization of the TATA box	62
promoter region of UGT1A1 gene	
3.2.2 GeneScan fragment analysis	64
3.3 Exon 1 (G71R) and exon 5 (G493R) mutations of UGT1A1	66
gene	
3.3.1 PCR amplification and visualization of exons 1 and 5 in	66
UGT1A1 gene	
3.3.2 Denaturing high performance liquid chromatography	68
(DHPLC) analysis for mutation screening	
3.3.2(a) DNA sizing (Helix sizing software)	68
3.3.2(b) Temperature mapping	70
3.3.2(c) Results of DHPLC testing	73
3.4 Summary of frequencies of the mutations and other clinical	80
data of the patients	
CHAPTER IV DISCUSSION	
4.1 Results of population study	88
4.2 Relevance of these findings to hyperbilirubinaemia	90
4.2.1 A(TA) <sub>7</sub> TAA variant in the promoter region of the UGT1A1	90
gene	
4.2.2 G71R mutation in exon 1 of the UGT1A1 gene	92
4.2.3 G493R mutation in exon 5 of the UGT1A1 gene	93

4.2.4 Combination of risk factors for neonatal jaundice	94
4.3 Other potential implications of the current study	97
4.3.1 Excretion of certain drug	97
4.3.2 Detoxification of dietary carcinogens	98
4.3.3 Other UGT1A isoforms	99
4.4 Strengths and limitations of the study	99
CHAPTER V CONCLUSION	102
BIBLIOGRAPHY	102
APPENDICES	109
PUBLICATIONS AND PRESENTATIONS	120

## LIST OF TABLES

## PAGE

Table 1.1	Risk	factors	for	nec	onatal	unconjugated	10
	hyperbi	ilirubinaemia	a				
Table 1.2	Risk fa	ctors for nec	onatal co	njuga	ted hyp	perbilirubinaemia	11
Table 1.3	Genoty	pes causing	Gilbert	syndro	ome		20
Table 2.1	Inclusio	on and exclu	sion crite	eria of	f the ne	onates for study	33
Table 2.2	Oligonu	ucleotide p	orimers	for	PCR	amplification of	42
	UGT1A	1 gene					
Table 2.3	Master	mix prepara	ation for	ΤΑΤΑ	box p	romoter region of	44
	UGT1A	1 gene in 3	0 µl total	volun	ne		
Table 2.4	Master	mix prepar	ation for	exor	ns 1 a	nd 5 of UGT1A1	46
	gene in	30 µl total v	volume				
Table 2.5	Manufa	cturers and	material	s use	d in the	e study	58
Table 3.1	Genoty	pic distribut	ion of TA	TA b	ox in p	romoter region of	75
	the UG	T1A1 gene	among N	lalay	neonat	es	
Table 3.2	Genoty	pic distribut	tion of G	971R	mutati	on in exon 1 of	75
	UGT1A	1 gene amo	ong Mala	y neo	nates		
Table 3.3	Genoty	pic distribut	ion of G	493R	t mutat	ion in exon 5 of	75
	UGT1A	1 gene amo	ong Mala	y neo	nates		
Table 3.4	Associa	ated other	risk fa	ctor	for hy	perbilirubinaemia	85
	subject	s with muta	ation in t	he U	GT1A1	gene with other	
	risk fac	ctors such	as ABO	inco	mpatib	ility and G-6-PD	
	deficier	су					

- Table 3.5Clinical data for baby 1 with simultaneous mutation of87TATA box promoter region and G71R in UGT1A1 gene
- Table 3.6Clinical data for baby 2 with simultaneous mutation of87TATA box promoter region and G71R in UGT1A1 gene

## LIST OF FIGURES

## PAGE

Figure 1.1	Schematic summary of the bilirubin metabolism	6
	pathway	
Figure 1.2	Pathway for heme degradation	7
Figure 1.3	Diagram for the regeneration of NADPH (reduced form)	15
	from NADP in the presence of G-6-PD enzyme. This is	
	a part of the antioxidant defense mechanism	
Figure 1.4	Human chromosome 2	23
Figure 1.5	Schematic diagram of the UDPGT1 gene	24
Figure 2.1	Flowchart of the study design	30
Figure 2.2	Samples were taken from various wards or sites	32
Figure 3.1	GeneScan analysis of the TATA box promoter region of	65
	UGT1A1 gene	
Figure 3.2	Chromatograms of DNA sizing for G71R and G493R	69
	mutations of UGT1A1 gene, compared to an external	
	standard pUC18 Hae III. Arrows show the expected	
	peak of chromatograms for the studied mutation	
Figure 3.3	Temperature map for G71R mutation showed that 59°C	71
	as an optimum temperature	
Figure 3.4	Temperature map for G493R mutation showed that	72
	62.5°C as an optimum temperature	
Figure 3.5	An example of chromatographic analyses for G71R	74
	and G493R mutations using Star Reviewer Software.	

Heteroduplex peak indicates for the presence of mutation and homoduplex peak indicates for the normal wild type.

Figure 3.6	Chromatograms of G71R mutation	76
i iyule 3.0	Chiomalograms of Gr IX mutation	1

- Figure 3.7 Chromatograms of G493R mutation 77
- Figure 3.8(a)Partial sequence electropherogram of the wild type for78exon 1 in UGT1A1 gene. Arrow shows the normal wildtype location in the absence of the G71R mutation
- Figure 3.8(b)
   Partial sequence electropherogram of the mutated
   78

   exon 1 in UGT1A1 gene. Arrow shows location of the
   671R mutation
- Figure 3.9(a)Partial sequence electropherogram of the wild type for79exon 5 in UGT1A1 gene. Arrow shows the normal wildtype location in the absence of the G493R mutation
- Figure 3.9(b) Partial sequence electropherogram of the mutated 79 exon 5 in *UGT1A1* gene. Arrow shows location of the G493R mutation
- Figure 3.10 Percentages of the subjects with normal and variants of 81 the TATA box promoter region in *UGT1A1* gene for jaundiced and non-jaundiced groups
- Figure 3.11 Percentages of the subjects with normal and mutations 82 of the G71R in exon 1 of *UGT1A1* gene for jaundiced and non-jaundiced groups
- Figure 3.12 Percentages of the subjects with normal and mutations 83 of the G493R in exon 5 of *UGT1A1* gene for jaundiced

xiii

and non-jaundiced groups

Figure 3.13Frequencies of the TATA box variant in promoter84region, G71R in exon 1 and G493R in exon 5 ofUGT1A1 gene for jaundiced and non-jaundiced groups

## LIST OF PLATES

## PAGE

Plate 3.1	Diagram shows extracted genomic DNAs from buffy coat			
	(enriched leukocytes), ready for PCR amplification of			
	UGT1A1 gene			
Plate 3.2	PCR products of TATA box promoter region	63		
Plate 3.3	PCR amplification of G71R in exon 1 of UGT1A1 gene	66		
Plate 3.4	PCR amplification of G493R in exon 5 of UGT1A1	67		
	gene			

## LIST OF ABBREVIATIONS

rpm       Revolutions per Minute         FSM       Full Scheme Milk         g       Gram         G493R       Glycine to Arginine at codon 493         G-6-PD       Glucose-6-phosphate dehydrogenase         G71R       Glycine to Arginine at codon 71         GSH       Reduced Glutathione         H <sub>2</sub> O       Water         H <sub>2</sub> O       Water         H <sub>2</sub> O       Hydrogen Peroxide         Ig       Anti-immunoglobulin         mg       Miligram         mg/dL       Miligram per deciliter         N       Total Sample Size         NADP       Nicotinamide Adenine Dinucleotide Phosphate         NCBI       National Centre for Biotechnology Information         O2       Oxygen         P229Q       Proline to Glutamine at codon 229         PBREM       Phenobarbital Response Enhancer Region         PCR       Polymerase chain reaction         PhIP       2-amino-1-methyl-6-phenylimidazo [4,5-f] pyridine         psi       Pound per square inch         SN-38       7-ethyl-10-hydroxycamptothecin         SN-38G       7-ethyl-10-hydroxycamptothecin         SN-38G       7-ethyl-10-hydroxycamptothecin         SN-38G       7-ethyl-10-hydroxyca	DH DN F pi F g G G G G G G Z 2 H H Ig m m N N O 2 P P P h p S S T T U U U U U U U U	2 2 3 3 3 3 3 3 3 3	Full Scheme Milk Gram Glycine to Arginine at codon 493 Glucose-6-phosphate dehydrogenase Glycine to Arginine at codon 71 Reduced Glutathione Oxidized Glutathione Water Hydrogen Peroxide Anti-immunoglobulin Miligram Miligram per deciliter Total Sample Size Nicotinamide Adenine Dinucleotide Phosphate National Centre for Biotechnology Information Oxygen Proline to Glutamine at codon 229 Phenobarbital Response Enhancer Region Polymerase chain reaction 2-amino-1-methyl-6-phenylimidazo [4,5-f] pyridine Pound per square inch 7-ethyl-10-hydroxycamptothecin 7-ethyl-10-hydroxycamptothecin Thymine Phenylalanine to Cystein at codon -3279 Uridyl diphosphoglucuronyl transferase Uridine-diphosphate glucuronosyltransferase 1 Uridine-diphosphoglucuronate-glucuronosyltransferases
---	--	--	---

## MUTASI - MUTASI GEN BILIRUBIN - URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE (*UGT1A1*) DI KALANGAN BAYI – BAYI YANG MENGALAMI HIPERBILIRUBINEMIA DALAM POPULASI MELAYU DI KELANTAN

#### ABSTRAK

Sindrom Gilbert berpunca daripada keabnormalan pada gen uridine diphosphate-glucuronosyltransferase 1A1 (UGT1A1) yang disebabkan oleh mutasi. Mutasi-mutasi ini berbeza bagi setiap populasi dan kebanyakannya menjadi faktor asas bagi jaundis di kalangan neonat. Objektif kajian ini adalah untuk menentukan frekuensi mutasi-mutasi berikut pada gen UGT1A1: A(TA)<sub>7</sub>TAA (penyebab yang lazim bagi sindrom Gilbert di kalangan orang-orang Kaukasia), G71R (penyebab utama pada populasi Jepun dan Taiwan) dan G493R (dijumpai pada wanita Melayu yang membawa mutasi homozigus bagi sindrom Crigler-Najjar jenis ke-2) di kalangan bayi - bayi Melayu di Kelantan yang mengalami hiperbilirubinemia dan juga di kalangan bayi - bayi normal sebagai kawalan serta membandingkan frekuensi mutasi-mutasi ini di antara kedua-dua kumpulan bayi tersebut. Analisis serpihan penyaringan gen (GeneScan) telah digunakan untuk mengesan varian A(TA)<sub>7</sub>TAA. Penyaringan mutasi kedua-dua G71R dan G493R telah dijalankan dengan menggunakan kromatografi cecair denaturasi berprestasi tinggi [Denaturing high performance liquid chromatography (DHPLC)]. Seramai 14 daripada 55 orang neonat dengan hiperbilirubinemia (25%) membawa mutasi A(TA)<sub>7</sub>TAA (10 heterozigus, 4 homozigus). Seramai 7 daripada 50 kawalan (14%) membawa mutasi ini (6

heterozigus, 1 homozigus). Frekuensi-frekuensi alel bagi bayi hiperbilirubinemia dan kawalan adalah masing-masing 16% dan 8% (p = 0.20). Heterozigositi mutasi G71R adalah lebih kurang sama bagi kedua-dua kumpulan (5.5% bagi bavi hiperbilirubinemia dan 6% bagi bayi yang tidak mengalami hiperbilirubinemia; p = 0.61). Seorang neonat (1.8%) dari kumpulan hiperbilirubinemia dan tiada neonat dari kumpulan kawalan mengalami mutasi heterozigus bagi G493R (p = 0.476). Kesimpulannya,  $A(TA)_7TAA$  lebih ketara daripada mutasi G71R dan G493R di dalam populasi Melayu di Kelantan. Walaupun frekuensi alel bagi mutasi A(TA)<sub>7</sub>TAA di dalam kumpulan hiperbilirubinemia adalah dua kali ganda daripada kumpulan bukan hiperbilirubinemia, namun perbezaannya adalah tidak signifikan secara statistik.

**Kata kunci**: Jaundis neonatal; gen *UGT1A1*; sindrom Gilbert; kromatografi cecair denaturasi berprestasi tinggi; penyaringan gen

#### ABSTRACT

Gilbert syndrome is caused by defects in the uridine diphosphateglucuronosyltransferase 1A1 (UGT1A1) gene. These mutations differ among different populations and many of them have been found to be genetic risk factors for the development of neonatal jaundice. The objectives of this study were to determine the frequencies of the following mutations in the UGT1A1 gene: A(TA)<sub>7</sub>TAA (the most common cause of Gilbert syndrome in Caucasians), G71R (more common in the Japanese and Taiwanese populations) and G493R (described in a homozygous Malay woman with Crigler-Najjar syndrome type 2) in a group of Malay babies in Kelantan with hyperbilirubinaemia and a group of normal controls and to compare the frequencies of these mutations between these group. The GeneScan fragment analysis was used to detect the A(TA)<sub>7</sub>TAA variant. Mutation screening of both G71R and G493R was performed using denaturing high performance liquid chromatography (DHPLC). Fourteen out of 55 neonates with hyperbilirubinaemia (25%) carried the A(TA)<sub>7</sub>TAA mutation (10 heterozygous, 4 homozygous). Seven out of 50 controls (14%) carried the mutation (6 heterozygous, 1 homozygous). The allelic frequencies for hyperbilirubinaemia and control patients were 16% and 8% respectively (p = 0.20). Heterozygosity for the G71R mutation was almost equal among both groups (5.5% for hyperbilirubinaemia patients and 6.0% for controls; p = 0.61). One subject (1.8%) in the hyperbilirubinaemia group and none of the controls were heterozygous for the G493R mutation (p = 0.476). In conclusion, the  $A(TA)_7TAA$  seems more common than the G71R and G493R mutations in the Malay population in Kelantan. Even though the allelic frequency of the  $A(TA)_7TAA$  mutation in the hyperbilirubinaemia group was twice that of the non hyperbilirubinaemia group, the difference did not reach statistical significance.

**Keywords**: Neonatal jaundice; *UGT1A1* gene; Gilbert syndrome; denaturing high performance liquid chromatography; GeneScan

#### **CHAPTER I**

#### INTRODUCTION

#### 1.1 Background of the study

Neonatal jaundice is a common phenomenon among newborn infants. In Malaysia most of the neonatal jaundice presents during the first week of life. Many babies develop only mild jaundice which is believed to be physiological. This physiological jaundice is thought to be due to an immaturity of the liver function in the newborn infant and due to the shorter life span of red blood cells carrying foetal haemoglobin.

On the other hand, many babies develop more severe jaundice, putting them at risk of developing bilirubin encephalopathy and kernicterus (American Academy of Pediatrics Subcommittee on Hyperbilirubinemia, 2004). Many causes have been identified for this more severe jaundice. The best known causes include haemolysis (such as rhesus incompatibility, ABO incompatibility or glucose - 6 - phosphate dehydrogenase (G-6-PD) deficiency), liver dysfunction (such as sepsis, Crigler-Najjar syndrome or metabolic disorders) and conditions which increase the enterohepatic circulation of bilirubin (such as breast feeding jaundice). A more detailed overview of the causes of neonatal jaundice and their importance will be given under subheading 1.4.

It is well known that in many cases of moderate or severe neonatal jaundice, the routine screening for common causes (including screening for G-6-PD deficiency, blood grouping, direct Coombs test and full blood picture) does not identify any cause. If in these cases there is neither a history of poor breast feeding, these babies are often labelled as having excessive physiological jaundice or more correctly, idiopathic pathological jaundice (Van Rostenberghe *et al.*, 2004). The term 'idiopathic' implies that the cause is unknown. Recent evidence in literature suggests that causal factors of this type of neonatal jaundice may be due to point mutations in exons or mutations in the promoter region of the uridine-diphosphate glucuronosyltransferase 1 (UGT1A1) gene. This gene encodes the enzyme responsible for the rate limiting step for the bilirubin excretion. A thorough literature review about these mutations will be presented under subheading 1.5 and 1.6.

Furthermore it is becoming increasingly clear that haemolysis in G-6-PD deficiency (and also ABO incompatibility) tends to be very mild and there is not much difference between babies developing neonatal jaundice and those not developing neonatal jaundice (Jalloh *et al.*, 2005, Kaplan *et al.*, 2005). Only about 20% of babies with G-6-PD deficiency develop jaundice requiring phototherapy. So then, what is the determining factor of which baby will and will not develop jaundice? It has been shown in some populations that again point mutations or mutations in the promoter region of the *UGT1A1* gene are very important associated factors (Kaplan *et al.*, 1997).

In different populations, different mutations in the *UGT1A1* gene have been identified and allelic frequencies of these mutations were very different depending on the population (Akaba *et al.*, 1998). No population study had been conducted so far regarding these mutations in any South-East Asian population. Since these mutations may be one of the determining factors whether or not a baby with G-6-PD deficiency will develop severe jaundice, it was felt that it is important to know in the Malaysian population whether mutations in this gene are common and whether they are related to the occurrence of jaundice.

That is the reason why this population study was undertaken in a Malay population in Kelantan to determine the frequency of three mutations in the *UGT1A1* gene in a group of jaundiced babies and in a group of babies with non-jaundiced as controls. The first mutation is the A(TA)<sub>7</sub>TAA mutation (also referred to as TATA box mutation) which is a mutation in the promoter region of the gene. This mutation is the major cause of Gilbert syndrome in Caucasians. The second mutation is the G71R mutation, a mutation in the first exon, which is common in the Taiwanese and Japanese populations. The third mutation studied is the G493R mutation which had been recently detected in a Malay family with Crigler-Najjar syndrome.

Before going into greater detail on the clinical aspects of neonatal jaundice and its causes, it is essential to have a clear understanding of the bilirubin metabolism itself which is described as follows.

3

#### 1.2 Bilirubin metabolism

Bilirubin is the end product of heme catabolism. It may play a role through its antioxidative properties in inhibition of lipid peroxidation. Bilirubin formation occurs in mononuclear phagocytes of liver, spleen and bone marrow, previously known as the reticuloendothelial system (Bhagavan, 2002, Ratnavel and Ives, 2005). In some conditions, bilirubin formation may occur in renal tubular epithelial cells, hepatocytes and macrophages.

About 75% of bilirubin is produced through haemolysis and most of the other 25% through ineffective erythropoiesis (Bhagavan, 2002, Shapiro, 2003). Minor contributions to the serum bilirubin are made by the breakdown of myoglobin and the cytochromes. About 34 to 35 mg of bilirubin is produced by the degradation of 1 g of haemoglobin (Thilo, 1999, Zaghloul and Schulze, 2001). One mg/dL of serum bilirubin is equivalent to 17.2 µmol/L of bilirubin (Thilo, 1999). In normal human metabolism, about 250 to 400 mg of bilirubin is generated daily.

When haemoglobin is broken down, the globin part is enzymatically hydrolysed into amino acids. On the other hand, heme part of the haemoglobin molecule is bound to the heme oxygenase (a microsomal enzyme) which oxidizes the  $\alpha$ -methane carbon of heme to  $\alpha$ -hydroxyhemin. Autoxidation to biliverdin (a blue-green pigment) occurs in the presence of oxygen and in the process iron and carbon monoxide (CO) are released (Figures 1.1 and 1.2). The released CO binds strongly to haemoglobin to form carboxyhaemoglobin (CO-Hb).

Measurement of this CO-Hb can give a reliable estimate the heme turn over (Bhagavan, 2002).

Biliverdin is converted to bilirubin which is catalyzed by biliverdin reductase in the presence of NADPH (Bhagavan, 2002). This lipid soluble bilirubin is bound in the serum to albumin. Bound bilirubin-albumin complex is transported to the liver and taken up by hepatocytes. In the liver, bilirubin is conjugated with two glucuronide molecules. This process is catalysed by the enzyme, uridyl diphosphoglucuronyl transferase (UDPGT) and is the rate limiting step of bilirubin excretion (Ives, 1997). Then, the bilirubin diglucuronide is excreted via the bile to the intestine. In the intestine, bilirubin diglucuronide is metabolized to stercobilins by the gut flora and excreted in the stool (Ratnavel and Ives, 2005).

However, bilirubin diglucuronide is cleaved by mucosal beta-glucuronidase in the absence of gut flora or if it stays for a prolonged time in the intestinal lumen. In this condition, bilirubin is reabsorbed through the portal system (the enterohepatic circulation). Free bilirubin is unconjugated bilirubin which is not bound to albumin. This bilirubin has a potential to cross the blood brain barrier and damage neurons (Thilo, 1999). A schematic summary of the bilirubin metabolism pathway is given in Figures 1.1 and 1.2.




Figure 1.1 Schematic summary of the bilirubin metabolism pathway




Figure 1.2 Pathway for heme degradation (Voet et al., 2002)

#### 1.3 Clinical aspects of neonatal jaundice

Jaundice or icterus can be defined as a yellowish discoloration of skin and sclera. This phenomenon is an indication of excess bilirubin in the blood. Clinical jaundice appears when the bilirubin level reaches about 90 µmol/L. Initially jaundice tends to appear in the face alone but as the hyperbilirubinaemia gets worse, other areas of the body become yellow as well. Generally it is assumed that jaundice reaching the abdomen indicates that the bilirubin level is about 250 µmol/L. If the legs are jaundiced it means there is severe hyperbilirubinaemia.

Hyperbilirubinaemia can be divided into two types depending on the conjugation of bilirubin to glucuronide molecules: i.e. unconjugated hyperbilirubinaemia and conjugated hyperbilirubinaemia.

#### **1.3.1** Unconjugated hyperbilirubinaemia (Indirect hyperbilirubinaemia)

Unconjugated hyperbilirubinaemia is caused by bilirubin which is not yet conjugated with glucuronide molecules (Thilo, 1999). This is the most common type of hyperbilirubinaemia found in neonates and its causes are listed in Table 1.1. In the next subheading the most important causes of neonatal jaundice will be elaborated on a bit further. In severe hyperbilirubinaemia, unconjugated bilirubin may cross the blood brain barrier and cause neurological problems (kernicterus and bilirubin encephalopathy), renal damage and death (Clarke *et al.*, 1997).

Kernicterus means jaundice of the nuclei in the brain. It was described by Christian Georg Schmorl in 1904. This pathological phenomenon is associated with a clinical entity, bilirubin encephalopathy. It is caused by bilirubin toxicity to the basal ganglia and various brainstem nuclei (Ives, 1997, 2004). This bilirubin toxicity is significantly higher among Asian newborns than among Caucasians (Akaba *et al.*, 1998).

The clinical syndromes of bilirubin encephalopathy are divided into two types; acute bilirubin encephalopathy and chronic bilirubin encephalopathy. Acute bilirubin encephalopathy is associated with lethargy, poor feeding, fluctuating hypotonia and hypertonia, high pitched cry, retrocollis, opisthotonus, impairment of upward gaze, fever, seizures and eventually death (Thilo, 1999, Shapiro, 2003). Chronic bilirubin encephalopathy is the sequel of the acute type. The clinical features of chronic bilirubin encephalopathy range from mild mental retardation and subtle cognitive disturbances to severe athetoid cerebral palsy, deafness and seizures.

#### 1.3.2 Conjugated hyperbilirubinaemia (Direct hyperbilirubinaemia)

This is an elevation of the serum bilirubin which is conjugated with glucuronide molecules. This water-soluble bilirubin diglucuronide is ready for excretion in bile and may increase when cholestasis occurs (Thilo, 1999). Conjugated hyperbilirubinaemia more commonly occurs after the first week of life, especially when the unconjugated hyperbilirubinaemia has decreased. The causes and the risk factors for conjugated hyperbilirubinaemia are listed in Table 1.2.

**Table 1.1** Risk Factors for Neonatal Unconjugated HyperbilirubinaemiaModified from the Clinical Use of Paediatric Diagnostic Tests(Barness and Barness, 2003)

Maternal Factors	Race or ethnic group -Native American, Asian, Greek Islander
	Complications during pregnancy -ABO incompatibility, Rhesus incompatibility, Diabetes mellitus
	Use of oxytocin in hypotonic solutions during labour
	Breast feeding: Breast-milk contains a competitive inhibitor of hepatic uridine-diphosphate glucuronosyltransferase
Perinatal Factors	Birth trauma -Ecchymoses, Cephalohematoma
	Infection -Viral -Bacterial -Protozoal
Neonatal Factors	Prematurity Genetic factors Familial disorders of conjugation -Crigler-Najjar syndrome (I and II), Gilbert syndrome
	Enzymatic defects causing haemolysis -Glucose-6-phosphate dehydrogenase deficiency -Pyruvate kinase deficiency, Hexokinase deficiency -Congenital erythropoietic porphyria
	Erythrocyte structural defects causing haemolysis -Elliptocytosis, Spherocytosis
	Polycythaemia Drugs -Chloramphenicol, Benzyl alcohol -Streptomycin sulfate, Sulfisoxazole Low intake of breast-milk (increased enterohepatic circulation)

**Table 1.2** Risk Factors for Neonatal Conjugated HyperbilirubinaemiaModified from the Clinical Use of Paediatrics Diagnostic Test(Barness and Barness, 2003)

Disorder	Supporting information
Infection	Improves with treatment.
Total parenteral nutrition	History of total parenteral nutrition
Biliary atresia	Pale stools.
α <sub>1-</sub> Antitrypsin deficiency	-
Alagille syndrome	Characteristic facies congenital abnormalities.
Galactosemia	Cataracts.Urinary reducing substances positive. Hypoglycemia, abnormal clotting.
Tyrosinemia type 1	Serum amino acids increased. Aminoacidemia. Hepatocellular disease. Increased serum α-fetoprotein.
Zellweger syndrome	Hypotonia. Dysmorphic features. Neurologic dysfunction.
Cystic fibrosis	Meconium ileus may occur.

#### 1.4 Common causes of neonatal jaundice

#### 1.4.1 Physiological jaundice

Physiological jaundice most commonly occurs on day 3 to day 5 of life and decreases the first week after birth. It is usually associated with mild to moderate jaundice believed to be caused by a variety of factors: cessation of bilirubin clearance of placenta, immaturity of hepatic enzymatic systems at birth which decreases the ability to conjugate bilirubin, decreased hepatic uptake of bilirubin, larger red cell volume, shortened erythrocyte life span of cells carrying foetal haemoglobin and increased enterohepatic circulation (Hintz *et al.*, 2001).

Physiological jaundice is the most common cause of neonatal jaundice. It tends to be more severe in Asian populations than in Caucasian and Black populations (Zaghloul and Schulze, 2001). Quite often however, the term is used incorrectly to denote severe cases of neonatal jaundice. If screening for common causes does not reveal any cause, neonatal jaundice tends to be labelled as excessive physiological jaundice. A better term for this severe jaundice might be idiopathic pathological jaundice (Van Rostenberghe *et al.*, 2004).

#### 1.4.2 Pathological causes

#### 1.4.2.1 Haemolytic causes

#### 1.4.2.1(a) ABO incompatibility

ABO incompatibility most commonly occurs when a baby with blood group A or B is born to a mother with type O blood group. In these cases antibodies made by the mother against the blood group antigens of the baby may cross the placenta and cause haemolysis. The presence of these maternal antibodies in the baby's blood is tested through the direct Coombs test, using heterologous anti-immunoglobulin (Kaplan and Hammerman, 2003). The Coombs test however has a high false negativity rate that may be related to a relatively low expression of the blood group antigens on the red blood cells of the neonate or to relatively low titres of antibodies. If jaundice occurs in ABO incompatibility, it typically starts on day 1 after birth (Thilo, 1999).

#### 1.4.2.1(b) Rhesus incompatibility


Rhesus incompatibility occurs when a Rhesus negative mother carries a Rhesus positive baby. This condition results in severe anaemia antenatally, causing hydrops fetalis. It is also called erythroblastosis fetalis (Thilo, 1999).

#### 1.4.2.1(c) Glucose-6-phosphate dehydrogenase deficiency

The enzyme glucose-6-phosphate dehydrogenase (G-6-PD) deficiency can be found in every cell in our body. It is used to protect cells (especially red blood cells) against oxidative damage. The glutathione which is oxidised is used for neutralisation of toxic agents such as hydrogen peroxide and organic peroxidases (Mehta *et al.*, 2000). To maintain the process, oxidized glutathione is directly changed back to the reduced form using hydrogen ions from NADPH. NADPH is formed from nicotinamide adenine dinucleotide phosphate (NADP) and this process is catalyzed by G-6-PD. Therefore, NADPH formation is disturbed in G-6-PD deficiency and this leads to fragility of the red blood cells in the presence of oxidative stresses. This process is illustrated in Figure 1.3. Residual G-6-PD activity and additional antioxidant enzymes such as catalase prevent significant haemolysis under physiological conditions but under oxidant stress conditions, severe haemolysis may occur (Mehta *et al.*, 2000, Kaplan and Hammerman, 2002).

G-6-PD deficiency is a major cause of neonatal jaundice (Mehta *et al.*, 2000) and is common in many developing countries with limited access to modern medical care. Half of the morbidity and mortality which is associated with neonatal jaundice may be caused by G-6-PD deficiency (Kaplan *et al.*, 2001a).

Classically it was believed that the neonatal jaundice in babies with G-6-PD deficiency is due to haemolysis. However in the majority of cases there is no identifiable oxidative stress and haemolysis has been found to be very mild and similar in G-6-PD deficient babies developing jaundice and those not developing jaundice (Jalloh *et al.*, 2005).



**Figure 1.3** Diagram for the regeneration of NADPH (reduced form) from NADP in the presence of G-6-PD enzyme. This is a part of the antioxidant defence mechanism. GSH: Reduced Glutathione; GSSG: Oxidized Glutathione (Kaplan and Hammerman, 2002).

The presence of other risk factors for jaundice in combination with G-6-PD deficiency may become the crucial factor determining whether or not a baby with G-6-PD deficiency gets jaundiced. Such factors may include a decrease in bilirubin conjugation that may be related to promoter polymorphism in the gene which controls the bilirubin conjugating enzyme UDP-glucuronosyltransferase (Kaplan *et al.*, 2001b). These findings were also supported by other studies (Bosma *et al.*, 1995, Beutler *et al.*, 2002).

Total serum bilirubin levels in G-6-PD deficient neonates rise gradually and eventually leading to jaundice. This gradual onset jaundice may cause the jaundice to be missed in babies discharged early from the postnatal ward. This is the reason that in Malaysia, all babies are screened and the G-6-PD deficient babies are monitored for 5 days in the ward, so phototherapy can be started early so as to prevent the need for exchange transfusion.

#### 1.4.2.1(d) Other causes of haemolysis

Another common cause of haemolysis is the extravasation of blood due to birth trauma. Extravasated blood is rapidly broken down and may cause severe hyperbilirubinaemia. Other less common causes of haemolysis can be found in Table 1.1.

#### 1.4.2.2 Non-haemolytic causes of neonatal jaundice

The common causes of jaundice without haemolytic disorder can be classified as follows:

- a) Increase of bilirubin production which is related to polycythaemia and swallowed blood.
- b) Decrease of bilirubin clearance, which is caused by UDPGT deficiency, resulting in Crigler-Najjar and Gilbert syndrome. A more detailed literature review on its relation to neonatal jaundice will be given in section 1.5. Decreased bilirubin clearance is also seen in hypothyroidism and breast feeding which is associated with jaundice.
- c) Unknown or multiple pathogeneses include altitude, racial differences, prematurity and bowel obstruction.

#### 1.5 Clinical syndromes associated with mutations in the UGT1A1 gene

Decreased bilirubin clearance is attributed to Crigler-Najjar and Gilbert syndrome, due to lack of UDPGT enzyme in the liver.

#### 1.5.1 Crigler-Najjar syndrome

Defects of the *UGT1A1* gene may occur in any of its five exons and contribute to Crigler-Najjar syndrome, either type I or II (Kadakol *et al.*, 2000). Crigler-Najjar syndrome type I is the severe form and was described by Crigler and Najjar in 1952 as a potentially lethal hyperbilirubinaemia (serum bilirubin 20–50 mg/dL) without liver disease or overt haemolysis (Crigler and Najjar, 1952).

Crigler-Najjar syndrome type II is an intermediate form with moderate elevations of the level of bilirubin (7–20 mg/dL). It is also known as Arias syndrome as it was described by Arias in 1962. It is commonly caused by a severe, but incomplete lack of *UGT1A1* activity in the liver (Seppen *et al.*, 1994).

#### 1.5.2 Gilbert syndrome

Gilbert syndrome was first described by Augustin Gilbert and Pierre Lereboullet in 1901. Patients with Gilbert syndrome commonly have mild and chronic unconjugated hyperbilirubinaemia with normal liver function and without overt haemolysis (Sugatani *et al.*, 2002). It is an inherited disorder of bilirubin metabolism.

Gilbert syndrome is considered to be a harmless disease, but it may be a risk factor for neonatal jaundice, especially in combination with haemolytic disorders, such as G-6-PD deficiency and ABO incompatibility (Sutomo *et al.*, 2002, Kaplan *et al.*, 2001a, Beutler *et al.*, 2002). There is still controversy whether Gilbert syndrome is inherited as a recessive or dominant trait. Schmid, (1995) assumed that it was inherited as an autosomal dominant trait while a study by Bosma *et al.*, (1995) suggested an autosomal recessive trait.

There may be different degrees of severity of the enzyme defect depending on the particular mutation. Some mutations are known to cause Crigler-Najjar syndrome type II in the homozygous state and Gilbert syndrome in the heterozygous state (Koiwai *et al.*, 1995). Phenobarbital treatment has been found to increase the enzyme activity resulting in a decrease in the serum bilirubin level (Black and Sherlock, 1970).

The incidence of Gilbert syndrome in the general population is about 3% to 10% (Iyanagi *et al.*, 1998, Yamamoto *et al.*, 1998). Hsieh and colleagues found that the TATA box mutation and G71R underlies the molecular background of Gilbert syndrome in the Taiwanese population.

Simultaneous occurrence of more than one mutations were also found in this population which resulted in higher level of bilirubin and caused a more severe form of Gilbert syndrome (Hsieh *et al.*, 2001). Since the *UGT1A1* gene is the focus of this study, a more in depth review on the *UGT1A1* gene is presented below. Several genotypes associated with Gilbert syndrome are listed in Table 1.3.

Refer to attached file: Table 1.3


#### 1.6 The UGT1A1 gene

The Uridine-diphosphoglucuronate-glucuronosyltransferases (UGTs) belong to the enzyme group of glycosyltransferases. UGTs in mammals have been classified into three families, based on the sequence similarity and structure of the gene: the UGT1, UGT2 and UGT8 (Meech and Mackenzie, 1997, Kadakol *et al.*, 2000). Within these families there are several isoforms. Only two isoforms in the UGT1A family (*UGT1A1* and *UGT1A4*) have bilirubin as a substrate but in humans only *UGT1A1* plays a significant role in bilirubin glucuronidation (Bosma *et al.*, 1994).

*UGT1A1* is located on chromosome 2q37 (Kiang *et al.*, 2005) as represented in Figure 1.4 and is the focus of the current study. It consists of 5 exons. Exons 2 to 5 are common exons of other isoforms within the UGT1A group (*UGT1A1-13*) and exon 1 is a unique exon for *UGT1A1* (Figure 1.5). The four common exons at 3' end encode the carboxyterminal domain for all isoforms of UGT which bind to UDP-glucuronic acid. The unique exon for each isoform at 5' end encodes the N-terminal domain for the enzyme which specifies the substrate for the isoform. At least 13 exons (for *UGT1A1* until *UGT1A13*) are located upstream of exon 2 (Ritter *et al.*, 1992, Mackenzie *et al.*, 1997, Watchko *et al.*, 2002).

A decrease in enzyme activity caused by defects or lesions in the *UGT1A1* gene results in unconjugated hyperbilirubinaemia (Sutomo *et al.*, 2002). Several mutations in *UGT1A1* gene have been reported to be associated with Gilbert

syndrome (e.g. the TATA box mutation (A(TA)<sub>7</sub>TAA), G71R and P229G) (Hsieh *et al.*, 2001). For the purpose of this study three mutations were studied.








Figure 1.5 Schematic diagram of the UDPGT1 gene (Watchko et al., 2002)

- a) The entire UGT1 gene complex (UGT1A1–UGT1A13) and exons 2–5 of the UGT1A1 gene
- b) The *UGT1A1* gene which consists of a normal TATA box in the promoter region and exons 2-5 of the gene